Menu
Logo

This year on EHA, we shared exciting new data on Imbruvica® (ibrutinib) in RESONATE-2

Media Center
‌
Watch professor Ghia reveal how results from up to 7 years of follow-up reinforce the ground-breaking advance in 1L CLL that Imbruvica represents.[1]

Categories / tags

CP-240988 - June 2021
© Janssen-Cilag NV 2021. This site is published by Janssen-Cilag NV which is solely responsible for its content. It is intended for Healthcare professionals in Belgium and Luxembourg.
Privacy PolicyLegal NoticeCookie Policy
Cookie Settings
Logo